BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 20155852)

  • 21. Detection of minimal residual disease in childhood B-acute lymphoblastic leukemia by 4-color flowcytometry.
    Baraka A; Sherief LM; Kamal NM; Shorbagy SE
    Int J Hematol; 2017 Jun; 105(6):784-791. PubMed ID: 28324281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunophenotypic analysis of T-acute lymphoblastic leukemia. A CD5-based ETP-ALL perspective of non-ETP T-ALL.
    Chopra A; Bakhshi S; Pramanik SK; Pandey RM; Singh S; Gajendra S; Gogia A; Chandramohan J; Sharma A; Kumar L; Seth R; Rai S; Kumar R
    Eur J Haematol; 2014 Mar; 92(3):211-8. PubMed ID: 24329989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: implications for minimal residual disease detection.
    Ciudad J; Orfao A; Vidriales B; Macedo A; Martínez A; González M; López-Berges MC; Valverde B; San Miguel JF
    Haematologica; 1998 Dec; 83(12):1069-75. PubMed ID: 9949623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Flow-cytometric monitoring of disease-associated expression of 9-O-acetylated sialoglycoproteins in combination with known CD antigens, as an index for MRD in children with acute lymphoblastic leukaemia: a two-year longitudinal follow-up study.
    Chowdhury S; Bandyopadhyay S; Mandal C; Chandra S; Mandal C
    BMC Cancer; 2008 Feb; 8():40. PubMed ID: 18241334
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunophenotypic modulation in pediatric B lymphoblastic leukemia and its implications in MRD detection.
    Thulasi Raman R; Anurekha M; Lakshman V; Balasubramaniam R; Ramya U; Revathi R
    Leuk Lymphoma; 2020 Aug; 61(8):1974-1980. PubMed ID: 32281503
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Flow cytometry in the differential diagnosis of lymphocyte-rich thymoma from precursor T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma.
    Li S; Juco J; Mann KP; Holden JT
    Am J Clin Pathol; 2004 Feb; 121(2):268-74. PubMed ID: 14983942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of CD81 and CD58 in minimal residual disease detection in pediatric B lymphoblastic leukemia.
    Tsitsikov E; Harris MH; Silverman LB; Sallan SE; Weinberg OK
    Int J Lab Hematol; 2018 Jun; 40(3):343-351. PubMed ID: 29500862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adult T-cell leukemia/lymphoma with an unusual CD1a positive phenotype.
    Juncà J; Botín T; Vila J; Navarro JT; Millá F
    Cytometry B Clin Cytom; 2014 Jul; 86(4):292-6. PubMed ID: 24115371
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Immunophenotyping characteristics of T-cell acute lymphoblastic leukemia].
    Chen LJ; Li JY; Wu YJ; Yang H; Qian SX; Wu HX; Lu H; Xu W; Sheng RL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):692-5. PubMed ID: 17708784
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Key Markers of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia.
    Xia M; Zhang H; Lu Z; Gao Y; Liao X; Li H
    J Pediatr Hematol Oncol; 2016 Aug; 38(6):418-22. PubMed ID: 27438018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antigen Expression on Blast Cells and Hematological Parameters at Presentation in Acute Lymphoblastic Leukemia Patients.
    Naeem S; Bukhari MH
    J Coll Physicians Surg Pak; 2015 Jun; 25(6):407-11. PubMed ID: 26100991
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy.
    Tembhare PR; Sriram H; Khanka T; Chatterjee G; Panda D; Ghogale S; Badrinath Y; Deshpande N; Patkar NV; Narula G; Bagal B; Jain H; Sengar M; Khattry N; Banavali S; Gujral S; Subramanian PG
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
    Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
    Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BIOMED-1 concerted action report: flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL).
    Porwit-MacDonald A; Björklund E; Lucio P; van Lochem EG; Mazur J; Parreira A; van den Beemd MW; van Wering ER; Baars E; Gaipa G; Biondi A; Ciudad J; van Dongen JJ; San Miguel JF; Orfao A
    Leukemia; 2000 May; 14(5):816-25. PubMed ID: 10803512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry].
    Liu YR; Wang H; Chang Y; Cheng YF; Fu JY; Zhang LP; Liu GL; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):327-31. PubMed ID: 16185473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-Study Group.
    Dworzak MN; Gaipa G; Schumich A; Maglia O; Ratei R; Veltroni M; Husak Z; Basso G; Karawajew L; Gadner H; Biondi A
    Cytometry B Clin Cytom; 2010 May; 78(3):147-53. PubMed ID: 20201055
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Measurable Residual Disease Detection in B-Acute Lymphoblastic Leukemia: The Children's Oncology Group (COG) Method.
    Borowitz MJ; Wood BL; Keeney M; Hedley BD
    Curr Protoc; 2022 Mar; 2(3):e383. PubMed ID: 35263042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: method and significance.
    Dworzak MN; Fritsch G; Panzer-Grümayer ER; Mann G; Gadner H
    Leuk Lymphoma; 2000 Jul; 38(3-4):295-308. PubMed ID: 10830736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PTK7: a new biomarker for immunophenotypic characterization of maturing T cells and T cell acute lymphoblastic leukemia.
    Jiang G; Zhang M; Yue B; Yang M; Carter C; Al-Quran SZ; Li B; Li Y
    Leuk Res; 2012 Nov; 36(11):1347-53. PubMed ID: 22898210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Shifts in expression of immunological cell markers in relapsed acute leukemia.
    Tomová A; Babusíková O
    Neoplasma; 2001; 48(3):164-8. PubMed ID: 11583283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.